2023-03-30 09:58:44 ET
- Pulmatrix press release ( NASDAQ: PULM ): FY GAAP EPS of -$5.46.
- Revenue of $6.1M (+17.3% Y/Y).
- Research and development expense was $18.2 million for the year ended December 31, 2022, as compared to $15.4 million for the year ended December 31, 2021; an increase of $2.8 million.
- General and administrative expense was $6.8 million for the year ended December 31, 2022, as compared to $6.4 million for the year ended December 31, 2021; an increase of $0.4 million.
- Pulmatrix's total cash and cash equivalents balance as of December 31, 2022 was $35.6 million.
For further details see:
Pulmatrix GAAP EPS of -$5.46, revenue of $6.1M